Working… Menu

Evaluation of the Clinical Effectiveness of a Collagen-ORC Antimicrobial Matrix in Full-Thickness, Neuropathic Diabetic Foot Ulcers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00235196
Recruitment Status : Completed
First Posted : October 10, 2005
Last Update Posted : October 13, 2006
Information provided by:
Ethicon, Inc.

Brief Summary:
This is a randomized (1:1), prospective, open label, multicenter, comparative study to be examine the effectiveness of Collagen-ORC Antimicrobial matrix, a new wound dressing, on diabetic foot ulcers.

Condition or disease Intervention/treatment Phase
Foot Ulcer Device: Collagen ORC Antimicrobial Matrix (CAM) Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Study to Evaluate the Clinical Effectiveness of a Collagen-ORC Antimicrobial Matrix in Full-Thickness, Neuropathic Diabetic Foot Ulcers
Study Start Date : July 2004
Study Completion Date : December 2005

Resource links provided by the National Library of Medicine

Drug Information available for: Collagen

Primary Outcome Measures :
  1. Clinical effectiveness of CAM in DFU by comparing the reduction in wound area between 2 treatment groups.

Secondary Outcome Measures :
  1. Rate of wound closure
  2. Ease of use and adverse events
  3. Wound odor
  4. Quality of life
  5. Wound characteristics

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • 18 years of age or older.
  • Ambulatory (i.e. walking is the primary method of mobilization. Crutches, walker, walking frame or other ambulation aids are permitted).
  • Diagnosed Type 2 diabetic (i.e. not juvenile onset).
  • Have a DFU on the plantar surface of either foot.
  • Have a DFU of >4 wks but <6 months duration.
  • Willing and capable of cooperating to the extent and degree required by the study protocol

Exclusion Criteria:

  • Be < 1cm2 or >10cm2 in area, by planimetry.
  • Demonstrate overt signs of infection.
  • Be located on the dorsal, lateral, or posterior heel area of the foot (Change 2, Amendment 1).
  • Have visible exposed bone or tendon.
  • Have an adjacent thermal injury or wound of an etiology other than diabetes.
  • Be within 5 cm of any other wound, regardless of etiology.
  • Have received enzymatic debriding agents in the past 7 days.
  • Have received topical antibiotic therapy in the past 7 days.
  • Be less than 1 cm2 or exceed 10cm2 in area by planimetry, after debridement.
  • Have exposed bone or tendon, after debridement

The study subject MUST NOT:

  • Have received previous treatment for the study ulcer by this Investigator.
  • Have more than 3 full thickness ulcers, in total.
  • Be pregnant or nursing an infant
  • Have a concurrent illness or condition which may interfere with wound healing, such as carcinoma, vasculitis, immune system disorders or connective tissue disorder.
  • Be a known alcohol or drug abuser.
  • Have received systemic corticosteroids, immunosuppressive or chemotherapeutic agents in the past 30 days.
  • Have received radiotherapy, which includes the lower extremity, at any time.
  • Have a marked Charcot foot or claw foot deformity which would limit the ability of the subject to wear or be compliant with the wearing of the standardized off-loading device used in this study.
  • Have received an investigational drug or device in the past 30 days.
  • Have a known hypersensitivity to bovine collagen, oxidized regenerated cellulose (ORC) or silver.
  • Be unwilling or unable to be fitted or compliant with the wearing of an ulcer off-loading device.
  • Known to be non-compliant or unlikely to complete the study.
  • Have ABPI < 0.7, OR, if ABPI >1.0 and toe pressure >0.6.
  • Have serum Creatinine > 3 mg/dL25. have Hgb A1C>9%

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00235196

Layout table for location information
United States, Florida
Wound Care Center
Ft. Lauderdale, Florida, United States
Foot and Ankle Institute of South Florida
South Miami, Florida, United States
United States, Pennsylvania
Penn North Centers for Advanced Wound Care
Warren, Pennsylvania, United States, 16365
Sponsors and Collaborators
Ethicon, Inc.
Layout table for investigator information
Study Director: James Hart, MD Ethicon, Inc.

Layout table for additonal information Identifier: NCT00235196     History of Changes
Other Study ID Numbers: 400-04-001
First Posted: October 10, 2005    Key Record Dates
Last Update Posted: October 13, 2006
Last Verified: October 2006
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetic Foot
Foot Ulcer
Pathologic Processes
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Leg Ulcer
Skin Ulcer
Skin Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Diabetic Neuropathies
Foot Diseases
Anti-Bacterial Agents
Anti-Infective Agents